The target's lead product, Tissuepatch, bonds with tissue to help control internal bleeding or prevent leaks from surgical incisions.

The medical technology company is formally introducing "embecta," expected to close in the second quarter of 2022, a name with ties to its past, patients and the future.

According to the medical technology company, the addition aligns with two tenets of its innovation agenda: to improve chronic disease outcomes and enable new care settings.

Francesca DeMartino succeeds Kristen Stewart in the role, who was named senior vice president of enterprise strategy and insights at the global medical technology company.

Sarah Hill, who leads sustainability efforts at Franklin Lakes-based BD, speaks with NJBIZ Editor Jeff Kanige about the company’s approach to ESG issues.

New syringe and needle lines at one of the company's Nebraska plants, completed as part of a public-private partnership with the Department of Health and Human Services' Assistant Secretary for Preparedness and Response, will provide the federal government with priority access to hundreds of millions of pieces of equipment.

The BD Veritor is an over-the-counter, rapid antigen diagnostic that uses computer vision technology in a smartphone to interpret and provide a digital display of testing results without a prescription, laboratory or long wait.

The BD COR PX/GX System integrates robotics and sample management software algorithms to automate the complete laboratory workflow from sample processing to demonstrative test result.

The executive vice president at BD and president of the company's Life Sciences business discussed the continued need for COVID-19 testing in general and the advantages of a combination test device.

Christopher DelOrefice will succeed the retiring Christopher Reidy effective Sept. 6 and gain immediate responsibility of the company's global finance organization.

Christopher Reidy will serve in his current role until a successor is chosen. He is also slated to join the board of directors of the company's diabetes care spinoff business upon its completion.

Increasing the company's resorbable mesh portfolio is a growth driver for the Franklin Lakes-based buyer and part of its strategy to better serve customers and their patients through advancing technologies.